Ziprasidone Hydrochloride Monohydrate

Ziprasidone (marketed as Geodon, Zeldox and Zipwell) was the fifth atypical antipsychotic to gain approval (February 2001) in the United States.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: 10-101-129

CAS No:146939-27-7 (net), 138982-67-9 (hydrochloride monohydrate)

Synonyms/Alias:CP-88059; 5-(2-(4-(1,2-Benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole · HCl · H2O

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
M.F/Formula
C21H21ClN4OS·ClH·H2O
M.W/Mr.
467.42
Labeling Target
5-hydroxytryptamine Receptor;
Dopamine Receptor
Application
Ziprasidone hydrochloride monohydrate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, acute mania and mixed states associated with bipolar disorder. Ziprasidone is also used off-label for depression, bipolar maintenance and PTSD.
Activity
Antagonist
Biological Activity
Ziprasidone (CP 88059) hydrochloride monohydrate, an antipsychotic agent, is an orally active combined 5-HT (serotonin) and dopamine receptor antagonist. Ziprasidone hydrochloride monohydrate has high affinity for rat (Ki: 3.4 nM)/human (2.5 nM) 5-HT1A receptors, 5-HT2A (0.42 nM), and dopamine D2 receptors (4.8 nM). Ziprasidone hydrochloride monohydrate is an inhibitor of norepinephrine reuptake.
Areas of Interest
Neurological Disease
Functions
Potassium channel regulator activity;
Virus receptor activity
Target
5-HT Receptor
Source#
Synthetic
Organism
Human
References

In the current work the kinetics of dehydration of ziprasidone hydrochloride monohydrate was studied by nonisothermal thermogravimetry. Ziprasidone hydrochloride monohydrate was heated from 30 to 150° with a heating rate of 5° per min under nitrogen gas atmosphere and weight loss data were collected. Powder X-ray difraction was used to characterize the solid before and after dehydration. The well accepted Coats-Redfern model fitting approach was applied to the thermogravimetry data for the kinetic analysis. Thirteen solid state reaction models were studied; among them one-dimensional diffusion model was found to be the best fit model for this reaction with an excellent correlation 0.9994. The Arrhenius parameters, activation energy, and pre-exponential factor were determined, the values were found to be 28 k.cal/mol and 9.53×1013 sec-1, respectively.

Ravikiran, A., Arthanareeswari, M., Kamaraj, P., & Praveen, C. (2013). Nonisothermal kinetics analysis of the dehydration of ziprasidone hydrochloride monohydrate by thermogravimetry. Indian journal of pharmaceutical sciences, 75(3), 361.

The findings of this study indicate that mild-to-moderate impairment of renal function does not result in clinically significant alteration of ziprasidone pharmacokinetics and therefore does not necessitate dose adjustment.

Aweeka, F., Jayesekara, D., Horton, M., Swan, S., Lambrecht, L., Wilner, K. D., ... & Turncliff, R. Z. (2000). The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. British journal of clinical pharmacology, 49(S1), 27-33.

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
cGMP Peptide ServicePeptide CDMOPeptide Analysis ServicesPeptide Synthesis ServicesPeptide Modification ServicesEpitope Mapping ServicesCustom Conjugation ServicePeptide Nucleic Acids Synthesis
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers